Moody Lynn & Lieberson LLC Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Moody Lynn & Lieberson LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 0.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,577 shares of the medical technology company’s stock after buying an additional 549 shares during the quarter. Stryker comprises 1.5% of Moody Lynn & Lieberson LLC’s investment portfolio, making the stock its 23rd biggest position. Moody Lynn & Lieberson LLC’s holdings in Stryker were worth $25,051,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Patton Albertson Miller Group LLC lifted its position in shares of Stryker by 1.5% during the fourth quarter. Patton Albertson Miller Group LLC now owns 20,894 shares of the medical technology company’s stock worth $7,523,000 after acquiring an additional 317 shares in the last quarter. Running Oak Capital LLC lifted its holdings in Stryker by 7.1% during the 4th quarter. Running Oak Capital LLC now owns 38,543 shares of the medical technology company’s stock worth $13,877,000 after purchasing an additional 2,561 shares in the last quarter. Grimes & Company Inc. boosted its stake in Stryker by 0.5% in the 4th quarter. Grimes & Company Inc. now owns 8,277 shares of the medical technology company’s stock worth $2,980,000 after purchasing an additional 38 shares during the period. Linden Thomas Advisory Services LLC grew its holdings in Stryker by 16.2% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 6,053 shares of the medical technology company’s stock valued at $2,179,000 after buying an additional 843 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its position in shares of Stryker by 0.7% during the fourth quarter. Geneos Wealth Management Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,047,000 after buying an additional 92 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

NYSE SYK opened at $394.08 on Friday. The company has a 50-day simple moving average of $376.11 and a two-hundred day simple moving average of $360.81. Stryker Co. has a 12-month low of $307.23 and a 12-month high of $398.20. The firm has a market cap of $150.23 billion, a price-to-earnings ratio of 42.24, a PEG ratio of 2.68 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.46 EPS. On average, equities analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s payout ratio is presently 36.01%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Wednesday. Citigroup upped their price target on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group lifted their price objective on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Tuesday, January 7th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $405.80.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.